RCAG
EW icon

Rehmann Capital Advisory Group’s Edwards Lifesciences EW Stock Holding History

Rehmann Capital Advisory Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$525K Buy
6,560
+161
+3% +$13.3K 0.03% 389
2025
Q4 		$546K Buy
6,399
+130
+2% +$10.7K 0.03% 368
2025
Q3 		$488K Buy
+6,269
New +$490K 0.03% 385
2025
Q2 		– Sell
-6,298
Closed -$456K – 620
2025
Q1 		$456K Sell
6,298
-19
-0.3% -$1.36K 0.03% 377
2024
Q4 		$468K Sell
6,317
-629
-9% -$44K 0.03% 370
2024
Q3 		$458K Sell
6,946
-904
-12% -$65.7K 0.03% 361
2024
Q2 		$725K Sell
7,850
-221
-3% -$19.6K 0.05% 254
2024
Q1 		$771K Sell
8,071
-112
-1% -$9.41K 0.06% 236
2023
Q4 		$624K Sell
8,183
-875
-10% -$60.9K 0.05% 264
2023
Q3 		$628K Buy
+9,058
New +$728K 0.06% 256
2023
Q2 		– Sell
-9,940
Closed -$822K – 557
2023
Q1 		$822K Sell
9,940
-114
-1% -$8.96K 0.08% 219
2022
Q4 		$750K Buy
10,054
+313
+3% +$24.1K 0.08% 223
2022
Q3 		$805K Buy
9,741
+106
+1% +$10.2K 0.09% 196
2022
Q2 		$916K Buy
9,635
+564
+6% +$58.4K 0.1% 172
2022
Q1 		$1.07M Buy
9,071
+46
+0.5% +$5.16K 0.1% 179
2021
Q4 		$1.17M Sell
9,025
-867
-9% -$101K 0.11% 174
2021
Q3 		$1.12M Sell
9,892
-151
-2% -$17.2K 0.11% 173
2021
Q2 		$1.04M Buy
10,043
+90
+0.9% +$8.48K 0.1% 175
2021
Q1 		$832K Buy
9,953
+245
+3% +$20.7K 0.09% 198
2020
Q4 		$886K Sell
9,708
-36
-0.4% -$2.99K 0.1% 172
2020
Q3 		$778K Buy
9,744
+17
+0.2% +$1.33K 0.1% 178
2020
Q2 		$672K Buy
9,727
+217
+2% +$15.4K 0.09% 187
2020
Q1 		$598K Buy
+9,510
New +$686K 0.1% 173
2019
Q3 		$672K Sell
9,171
-51
-0.6% -$3.58K 0.08% 133
2019
Q2 		$568K Sell
9,222
-54
-0.6% -$3.27K 0.07% 226
2019
Q1 		$592K Buy
9,276
+48
+0.5% +$2.74K 0.08% 192
2018
Q4 		$471K Buy
9,228
+18
+0.2% +$911 0.07% 141
2018
Q3 		$534K Buy
9,210
+15
+0.2% +$734 0.07% 206
2018
Q2 		$446K Sell
9,195
-96
-1% -$4.48K 0.06% 228
2018
Q1 		$432K Hold
9,291
– – 0.07% 214
2017
Q4 		$349K Buy
9,291
+294
+3% +$10.8K 0.06% 251
2017
Q3 		$328K Buy
8,997
+2,328
+35% +$88.8K 0.06% 244
2017
Q2 		$263K Sell
6,669
-3,510
-34% -$128K 0.05% 286
2017
Q1 		$319K Buy
10,179
+165
+2% +$5.17K 0.05% 258
2016
Q4 		$313K Buy
10,014
+1,308
+15% +$42.4K 0.06% 260
2016
Q3 		$350K Buy
8,706
+927
+12% +$34.9K 0.07% 227
2016
Q2 		$259K Sell
7,779
-261
-3% -$8.93K 0.05% 290
2016
Q1 		$236K Sell
8,040
-384
-5% -$10.6K 0.05% 295
2015
Q4 		$222K Buy
+8,424
New +$219K 0.05% 305

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Rehmann Capital Advisory Group's EW Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its Edwards Lifesciences (EW) stake by 2.5% in Q1 2026, buying an estimated $13.3K and bringing the position to 6,560 shares worth $525K. The position accounts for 0.03% of the portfolio, ranked #389.

Rehmann Capital Advisory Group first reported a position in EW in Q4 2015 and has held it in 39 quarters since. The position peaked at $1.17M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Rehmann Capital Advisory Group held 6,560 shares of Edwards Lifesciences worth $525K as of Q1 2026.
  • Rehmann Capital Advisory Group bought 161 Edwards Lifesciences shares in Q1 2026, an estimated $13.3K.
  • Edwards Lifesciences made up 0.03% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #389 holding.
  • Rehmann Capital Advisory Group first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 39 quarters since.
  • Rehmann Capital Advisory Group's Edwards Lifesciences position peaked at $1.17M in Q4 2021.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.